Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Basic & Translational Research

Squalamine on Trial

Squalamine may have fascinating origins – originally derived from the livers of the dogfish shark – but as a treatment for wet AMD it has so far failed to have any “bite.” An antiangiogenic steroid, this small molecule drug has been shown to stop the growth of abnormal blood vessel development and reduce vascular endothelial growth factor (VEGF), showing potential in cancer therapies as well as in treatment for macular diseases.

Initial trials discovered that it inhibited neovascularization in the iris when injected intravenously, and was found to induce regression of retinopathy in mouse models.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register